2068 Bioconjugate Chem., Vol. 21, No. 11, 2010
Adak et al.
J ) 6.6 Hz), 1.03 (d, 1.3H, J ) 6.6 Hz). MS (ESI) calcd for
C34H64N4O23Na [M+Na]+ m/z 919.38; found: m/z 919.70.
4.91 (d, 2H, J ) 11.2 Hz), 4.87 (d, 1H, J ) 8.6 Hz), 4.82 (d,
2H, J ) 9.3 Hz), 4.78 (d, 2H, J ) 10.6 Hz), 4.75 (d, 1H, J )
11.2 Hz), 4.65 (d, 2H, J ) 11.2 Hz), 4.61 (d, 2H, J ) 8.6 Hz),
4.57 (d, 1H, J ) 4.0 Hz), 4.49 (d, 1H, J ) 7.8 Hz), 4.42 (d,
1H, J ) 10.2 Hz), 4.39 (d, 1H, J ) 6.4 Hz), 4.34 (d, 1H, J )
12.0 Hz), 4.24 (d, 2H, J ) 12.0 Hz), 4.20 (d, 1H, J ) 10.6
Hz), 4.07 (dd, 1H, J ) 5.8, 11.2 Hz), 4.00 (d, 1H, J ) 4.0 Hz),
3.95 (t, 1H, J ) 12.0 Hz), 3.84 (t, 1H, J ) 7.4 Hz), 3.77 (dd,
1H, J ) 4.0, 10.0 Hz), 3.70 (d, 1H, J ) 9.8 Hz), 3.65-3.62
(m, 1H), 3.55 (t, 1H, J ) 8.9 Hz), 3.50 (d, 1H, J ) 7.5 Hz),
3.46 (d, 1H, J ) 8.0 Hz), 3.42 (dd, 1H, J ) 2.6, 8.0 Hz),
3.37-3.32 (m, 2H), 2.19 (s, 3H), 2.01 (s, 3H), 1.95 (s, 3H),
1.60 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 170.72, 170.31,
170.22, 169.91, 138.79, 138.53, 138.40, 138.34, 138.22, 137.44,
137.25, 129.04, 128.94, 128.71, 128.32, 128.19, 127.93, 127.87,
127.73, 127.53, 127.34, 127.07, 103.32, 102.76 (2C), 82.79,
81.95, 80.78, 76.10, 75.58, 75.33, 74.45, 73.51, 73.38, 72.07,
71.19, 70.96, 68.75, 68.31, 66.71, 61.35, 51.01, 23.41, 21.08,
20.87. MS (ESI) 1324.25 [M+Na]+. MS (MALDI-TOF) calcd
for C75H83NO19Na [M+Na]+ m/z 1324.5456; found: m/z
1324.5573.
Heptanediol-Linked Lactose-Bishydrazide Conjugate (9). This
compound was similarly prepared as that described above,
starting from lactose (50 mg, 0.146 mmol) and 1,7-heptanediol
bishydrazide 5 (201 mg, 0.736 mmol). Purification by RP-HPLC
(1-50% aq CH3CN gradient over 45 min) yielded glycocon-
jugate 9 as a light-yellow oil (54 mg, 62%). 1H NMR (400 MHz,
CD3OD) δ 4.30 (d, 1H, J ) 7.6 Hz), (d, 1H, J ) 8.2 Hz), (d,
1H, J ) 4.4 Hz), 3.97 (s, 2H), 3.83-3.77 (m, 2H), 3.67-3.59
(m, 4H), 3.54-3.45 (m, 4H), 3.41-3.35 (m, 2H), 3.22-3.19
(m, 1H), 1.92-1.69 (m, 14H). 13C NMR (100 MHz, CD3OD)
δ 181.97, 173.86, 103.51, 89.97, 78.93, 76.39, 75.95, 75.52,
73.09, 71.55, 70.84, 69.18, 61.66, 61.01, 60.84, 23.98, 20.65,
20.44, 20.37. MS (ESI) calcd for C23H45N4O14 [M+H]+ m/z
601.28; found: m/z 601.09.
2-Deoxy-3,4,6-tri-O-acetyl-2-trichloroacetamido-ꢀ-D-galactopy-
ranosyl-(1f4)-2,4,6-tri-O-benzyl-ꢀ-D-galactopyranosyl-(1f4)-
1,2,3,6-tetra-O-benzyl-D-glucopyranose (12). D-Galactosamine
thiophenyl glycoside 10 (51) (36.8 mg, 0.066 mmol) and lactose
derivative 11 (52) (43.0 mg, 0.044 mmol) were stirred under
argon in dry CH2Cl2 (2 mL) for 30 min at rt in the presence of
freshly activated, powdered 4 Å molecular sieves. The reaction
mixture was cooled to -70 °C, then treated with N-iodosuc-
cinimide (NIS, 17.8 mg, 0.079 mmol) and a catalytic amount
of triflic acid (TfOH, 2.0 mg, 0.0132 mmol). The reaction
mixture was slowly warmed to 0 °C, then stirred for an
additional 4 h at rt. The reaction mixture was then neutralized
with a few drops of triethylamine and filtered over a pad of
Celite with rinsing by CH2Cl2. The mixture was washed with a
10% Na2SO3 solution followed by water, and the aqueous layer
was extracted twice with CH2Cl2. The organic phases were
collected and dried over anhydrous Na2SO4 and concentrated
then purified by silica gel chromatography (EtOAc/hexanes 2:3)
2-Acetamido-2-deoxy-ꢀ-D-galactopyranosyl-(1f4)-ꢀ-D-galac-
topyranosyl-(1f4)-D-glucopyranose (2). A solution of triacetate
13 (100 mg, 0.076 mmol) in dry methanol (5.0 mL) was treated
at rt with a catalytic amount of NaOMe in methanol (1 M, 32
µL). The reaction mixture was stirred for 1 h at rt and then
treated with Dowex 50WX8 (H+) resin (500 mg), filtered, and
concentrated to dryness. The partially deprotected trisaccharide
was dissolved in MeOH (5 mL) and treated with a catalytic
amount of Pd(OH)2 on charcoal (80 mg, 20% on active carbon),
purged with H2, and stirred under an H2 atmosphere for 12 h.
The catalyst was filtered through a pad of Celite, and the filtrate
was concentrated to yield pulmonary trisaccharide 2, as an off-
white solid (38 mg, 90% over two steps). 1H NMR (400 MHz,
CD3OD) δ 4.61 (dd, 1H, J ) 2.9, 8.4 Hz), 4.48 (d, 1H, J ) 7.2
Hz), 4.33 (d, 1H, J ) 7.7 Hz), 4.00 (d, 1H, J ) 1.7 Hz),
3.90-3.82 (m, 4H), 3.79-3.75 (m, 2H), 3.71-3.64 (m, 2H),
3.62-3.58 (m, 4H), 3.51-3.46 (m, 4H), 3.42-3.39 (m, 1H),
2.02 (s, 3H). 13C NMR (100 MHz, CD3OD) δ 175.12, 105.12,
104.43, 99.25, 93.69, 80.93, 78.29, 76.82, 76.49, 76.27, 76.00,
74.68, 74.38, 72.59, 69.91, 62.63, 61.95, 61.62, 55.27, 23.15.
MS (ESI) calcd for C20H35NO16Na [M+Na]+ m/z 568.47; found:
m/z 568.11.
1
to afford trisaccharide 12 as a yellow oil (52.2 mg, 84%). H
NMR (400 MHz, CDCl3) δ 7.44-7.25 (m, 35H, ArH), 6.23 (d,
1H, J ) 10 Hz, NH), 5.26 (d, 1H, J ) 2.8 Hz), 4.97 (d, 2H, J
) 12.0 Hz), 4.94 (d, 2H, J ) 12.0 Hz), 4.88 (d, 2H, J ) 8.0
Hz), 4.85 (d, 2H, J ) 8.0 Hz), 4.81 (d, 2H, J ) 9.6 Hz), 4.78
(d, 2H, J ) 8.0 Hz), 4.71 (d, 2H, J ) 8.0 Hz), 4.66 (d, 2H, J
) 12.0 Hz), 4.51 (d, 1H, J ) 8.0 Hz), 4.49 (d, 1H, J ) 8.0
Hz), 4.44 (d, 2H, J ) 12.0 Hz), 4.13-3.98 (m, 5H), 3.90 (dd,
2H, J ) 6.0, 11.2 Hz), 3.74-3.67 (m, 2H), 3.62-3.59 (m, 1H),
3.56 (d, 2H, J ) 9.2 Hz), 3.49 (t, 1H, J ) 7.6 Hz), 3.36 (d, 1H,
J ) 9.6 Hz), 2.09 (s, 3H), 2.03 (s, 3H), 1.99 (s, 3H). 13C NMR
(100 MHz, CDCl3) δ 170.49, 170.44, 170.30, 162.00, 139.15,
138.66, 137.84, 137.56, 129.00, 128.88, 128.57, 128.42, 128.30,
128.16, 128.00, 127.94, 127.83, 127.70, 127.59, 102.77, 99.51,
92.53, 82.53, 81.76, 82.53, 81.76, 76.11, 75.43, 75.06, 74.32,
73.88, 71.29, 70.64, 69.95, 68.20, 66.31, 60.87, 53.43, 20.87,
20.78, 20.68. MS (MALDI-TOF) calcd for C75H80Cl3NO19Na
[M+Na]+ m/z 1426.4287; found: m/z 1426.4573.
Fluorescein-Labeled 2′-Fucosyllactose Bishydrazide Conjugate
(14). A solution of glycoconjugate 8 (2.2 mg, 2.4 µmol) and
fluorescein isothiocyanate (FITC, 1.14 mg, 2.9 µmol) in
anhydrous methanol was treated with N,N-diisopropylethylamine
(1.2 µL, 9.8 µmol) and stirred for 10 h at rt. The reaction mixture
was concentrated and the residue was purified by RP-HPLC
(1-30% aq CH3CN gradient over 45 min) to yield FITC
conjugate 14 as a greenish-yellow solid (2.1 mg, 67%). 1H NMR
(400 MHz, CD3OD) δ 8.18 (d, 1H, J ) 8.9 Hz), 7.50 (d, 1H,
J ) 2.0 Hz), 7.36 (d, 1H, J ) 8.8), 4.21 (br s, 2H), 4.14 (d, 1H,
J ) 9.4 Hz), 4.05 (d, 1H, J ) 9.3 Hz), 3.79-3.78 (m, 4H),
3.74-3.62 (m, 37H), 3.52-3.50 (m, 2H), 3.45-3.42 (m, 1H),
3.24-3.23 (m, 2H), 3.21-3.17 (m, 2H), 3.12-3.09 (m, 1H),
2.00 (3, 3H). MS (MALDI) calcd for C55H76N5O28S [M+H]+
m/z 1290.43; found: m/z 1290.27.
2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-ꢀ-D-galactopyranosyl-
(1f4)-2,4,6-tri-O-benzyl-ꢀ-D-galactopyranosyl-(1f4)-1,2,3,6-
tetra-O-benzyl-D-glucopyranose (13). A solution of trichloro-
acetamide 12 (50 mg, 0.036 mmol) in dry benzene (1 mL) was
treated with tributyltin hydride (52.4 mg, 0.18 mmol) and 2,2′-
azobis(isobutyronitrile) (AIBN, 5.86 mg, 0.036 mmol). The
mixture was degassed for 15 min with argon, then heated to
reflux for 1 h, cooled to rt, and poured into an aq solution of
NaHCO3, and extracted with CH2Cl2. The combined extracts
were washed with brine, dried over anhydrous Na2SO4, and
concentrated under reduced pressure. Purification of the residue
by silica gel chromatography (EtOAc/hexanes 1:1) afforded
PhotoactiVe Glycan-Bishydrazide Conjugates (15-17). In a
typical reaction, a solution of pulmonary trisaccharide-
bishydrazide conjugate 7 (11 mg, 11.5 µmol) and N-5-azido-
2-nitrobenzoyloxy-succinimide (ANB-NOS, 5.3 mg, 17.3 µmol)
in anhydrous DMF (1 mL) was treated with N,N-diisopropyl-
ethylamine (2.0 µL, 12.7 µmol) and stirred for 12 h at rt,
protected from light. The reaction mixture was concentrated,
and the residue was purified by RP-HPLC (1-30% aq CH3CN
gradient over 45 min) to afford ANS conjugate 16 as a brown
1
acetamide 13 as a yellow oil (32.5 mg, 70%). H NMR (400
MHz, CDCl3) δ 7.53-7.23 (35H, ArH), 5.47 (d, 1H, J ) 8.9
Hz, NH), 5.32 (d, 1H, J ) 2.7 Hz), 4.97 (d, 1H, J ) 8.0 Hz),